177Lu-LNC1011 in Patients With Metastatic Castration-resistant Prostate Cancer - Trial NCT06250244
Access comprehensive clinical trial information for NCT06250244 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking Union Medical College Hospital and is currently Recruiting. The study focuses on Metastatic Castration-resistant Prostate Cancer. Target enrollment is 9 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking Union Medical College Hospital
Timeline & Enrollment
N/A
Oct 01, 2023
Oct 01, 2024
Primary Outcome
Dosimetry of normal organs and tumors,Hematologic adverse events collection,Liver and renal toxic events collection
Summary
This study employed an open-label, non-randomized design, representing the first human trial
 of its kind. It utilized a standard 3+3 dose-escalation approach, focusing on patients with
 metastatic castration-resistant prostate cancer, initiating treatment at a dose of 1.85 GBq
 over a 6-week period. Subsequent cohorts underwent sequential 50% dose escalations until the
 observation of dose-limiting toxicity (DLT).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06250244
Non-Device Trial